Edinburgh cell therapy manufacturer RoslinCT has been awarded a Research & Development grant from Scottish Enterprise to speed up the digital transformation of its manufacturing operations in Scotland.
The grant, worth up to £7.25 million, forms part of the company’s digital expansion plan. This is a multi-year initiative to strengthen its integrated digital and AI capabilities. The programme will develop a digitally integrated manufacturing environment, with the aim of improving operational efficiency, data connectivity and manufacturing excellence across the company’s operations.
RoslinCT is a contract development and manufacturing organisation (CDMO) for cell therapy. The company says a more connected, data-driven environment will put it in a better position to support clients through the product lifecycle and help bring cell therapies to patients faster and more cost-effectively. The project is also expected to contribute to Scotland’s life sciences sector through job creation and long-term economic growth.
Peter Coleman, chief executive of RoslinCT, said: “This support from Scottish Enterprise represents an important investment in the future of advanced therapy manufacturing in Scotland. Digital technologies are transforming how cell therapies are developed and manufactured, enabling greater efficiency, consistency and scalability while maintaining the highest quality standards.
“At RoslinCT, we are committed to building world-class manufacturing capabilities that help our clients bring innovative therapies to patients faster. This programme will strengthen our digital infrastructure, support continued innovation and reinforce Scotland’s position as a leading destination for cell and gene therapy manufacturing.”
Adrian Gillespie, chief executive of Scottish Enterprise, said: “Scotland’s life sciences sector has built a strong international reputation for innovation and expertise, and RoslinCT’s ambitious digital programme demonstrates their continued leadership in this field.
“This R&D project is a prime example of how Scottish Enterprise support can enable innovation at scale and strengthen competitiveness in global markets.”
Tom Arthur, Minister for Business and Fair Work, said: “This Scottish Enterprise grant is good news for Edinburgh, good news for Scotland’s life sciences sector and good news for the advancement of vitally important work that is improving and saving lives across the world.
“Over the last twenty years, RoslinCT has established itself as a Scottish success story, delivering and manufacturing life-changing therapies for cancer, genetic disorders and other complex medical conditions.
In Case You Missed It:
Clas-Sic Lands £1.9M From Scottish Enterprise’s New Capital Grant, Part of a £12M Upgrade at Its Fife Wafer Fab
Glasgow Tech Company Targets Transatlantic Growth With £1.25m Funding Boost
Nebu~Flow’s £2m grant marks Scottish Enterprise’s latest step in long-term backing for Glasgow inhaled-medicine spinout
Cirrus Logic wins Scottish Enterprise grant to build next-generation smart-energy platform in Edinburgh
“The Scottish Government and our enterprise agencies recognise the importance of helping our life sciences sector remain internationally competitive and will continue supporting and investing in our fantastic, world-renowned innovation.”
RoslinCT has 22 cGMP cell therapy suites across sites in Edinburgh and Hopkinton, Massachusetts. It was founded in 2005 and is a GHO Capital portfolio company.
